


CHIRAL POOL SYNTHESIS OF 8-HYDROXYMETHYL-"9-OXA"-ANTHRACYCLINONES

Hanh Dufat-Trinh Van, Francois Tillequin, Claude Monneret, and Michel Koch*
 Departement de Pharmacognosie associé au CNRS, UA n°484, Faculté de Pharmacie, 4 avenue de l'Observatoire, 75270 Paris Cedex 06, France

Abstract - The synthesis of title compounds from (R)-2,3-O-isopropylidene-glyceraldehyde and leucoquinizarin is reported.

Doxorubicin (1) and daunorubicin (2) are glycoside antibiotics widely used in the chemotherapeutic treatment of different human cancers¹.



1 R = OH

2 R = H

3 R = H


4 R = β(N-dimethylacosamine)

5 R = H or sugar

On the other hand, different pyranonaphthoquinone antibiotics including kalafungin (3) or its enantiomer nanaomycin D and closely related nanaomycin A have been shown to possess significant antimicrobiological properties². It has also been postulated that these compounds would possess some antineoplastic activities as bioreductive alkylating agents³. This has been supported by the recent discovery of lactoquinomycin (4)⁴, an amino-glycoside of kalafungin which displayed antitumor activity although its mechanism of action has not yet been reported.


Synthesis of new analogs of 1 and 2 with an oxygen in the A ring instead of both the side-chain and axial OH at C-9 and with a hydroxymethyl side-chain at C-8 such as the 5,12-dihydroxy-3-hydroxymethyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11-dione (R = H), has been undertaken. Intercalation with native DNA must be less marked with these new glycosides of general formula 5 than with 1 and 2 since it

has been shown on different models⁵ that 9-OH and 13 C=O strongly participate but, in contrast, they could act as more powerful alkylating agent after bioreduction³. A synthetic strategy to elaborate such a tetracyclic skeleton followed the general A + BCD route which has been already successfully used in our laboratory⁶. With the same goal in mind to synthesize enantiomerically pure compounds to avoid the complex and wasteful separation of diastereoisomers after glycosidation with loss of the valuable amino-sugar moiety, (R)-2,3-O-isopropylidenglyceraldehyde (6) was used as chiral precursor⁷ of ring A. Aldol condensation of this latter with anion of leucoquinizarin (7), precursor of rings BCD could be a possible way to obtain under Marschalk conditions⁸ and in the first step, a chiral β -alkylanthraquinone. Since this reaction gave three products in a temperature-dependent ratio, efforts were directed towards conditions which gave the desired compound 8 as major product. Thus at 40°C, 8 (m p 149-152°C ; $[\alpha]_D^{20}$ -40° in CH₂Cl₂)⁹ was isolated in 46 % yield along with a small amount of the corresponding hydroxy-derivative (9) (mixture of diastereoisomers¹⁰, 7 %) and 24 % of 10 (m p 143-145°C)¹¹. A second alkylation of 8 under Marschalk conditions with formaldehyde at room temperature for 1 h, afforded 11 (m p 149°C ; $[\alpha]_D^{20}$ -122° in CH₂Cl₂) which was isolated in 98 % yield.




Photochemical bromination of 11 (NBS, 2,2'-azobis(2-methylpropanenitrile), CCl₄, 2 h) led to 13 in 20 % yield (m p 105°C, $[\alpha]_D^{20}$ -106° in CH₂Cl₂) along with the mixture of compounds 14 resulting from bromination of one of the two methyl groups of the acetal ring. Owing to this difficulties, in a further attempt, the acetal ring of 11 was removed under acidic conditions (1N HCl-MeOH, room temperature, 2 h) to give 15 in quantitative yield (m p 174°C ; $[\alpha]_D^{20}$ -107° in MeOH). After peracetylation of 15 (Ac₂O, C₅H₅N, room temperature, 48 h), giving 16 (m p 135°C ; $[\alpha]_D^{20}$ +33° in CHCl₃) in quantitative yield, benzylic bromination was performed by irradiation of 16 (1,3-dibromo-5,5'-dimethylhydantoin, CCl₄, 2 h)¹² to obtain 19 (m p 140°C) in 77 % yield.

On the other hand, ortho-dialkylquinizarin (12) must be prepared in a way different from that previously used to synthesize 11 since Marschalk condensation of 8 with CH_3CHO led to 21 (m p 148-150°C). Nevertheless, 12 (m p 158°C ; $[\alpha]_D^{20}$ -50° in CH_2Cl_2) could be obtained in 16 % yield starting from 2-ethylquinizarin (22) by aldol condensation with (R)-2,3-O-isopropylidenglyceraldehyde. Access to 20 (mixture of diastereoisomers) involved the same sequence of reactions as that previously used for the synthesis of 19 : i) cleavage of the acetal ring , ii) peracetylation , iii) photochemical bromination (12 → 17 → 18 → 20).




Heating 19 under reflux in a methanolic solution previously saturated with HCl gas gave quantitatively the required aglycon (23)¹³ (m p 190°C ; $[\alpha]_D^{20}$ -139° in CHCl_3). The same reaction applied to 20 led in 60 % overall yield to an equimolecular mixture of diastereoisomers 24¹⁴ (m p 200°C ; $[\alpha]_D^{20}$ -113° in CHCl_3) and 25¹⁵ (m p 238°C ; $[\alpha]_D^{20}$ +20° in CHCl_3) easily separated after column chromatography (silica gel, CH_2Cl_2). The absolute configuration at C-1 of both compounds could be established from their ¹³C nmr spectra. The spectrum of 24 exhibits two aliphatic $\underline{\text{C}}\text{H}$ signals at 71.8 and 73.3 ppm which correspond to the presence of two pseudo-axial substituents at C-3 and C-1 whereas the corresponding signals located at 65.8 and 68.3 ppm for 25 indicate a pseudo-axial and a pseudo-equatorial substituent on the A ring. Furthermore, these latter values were in good agreement

with the data published for nanaomycin A¹⁶. From these spectra, it could be deduced that the configurations were (1S,3S) for 24 and (1R,3S) for 25



23



24 R₁ = H ; R₂ = CH₃

25 R₁ = CH₃ ; R₂ = H

Several glycoside derivatives with amino-deoxy-sugar or deoxy-sugar have been prepared with both new aglycons. They have shown no significant antibiotic or antitumour activity and details for their preparation and for biological results will be reported later on.

ACKNOWLEDGMENTS


We are grateful to Hoechst Laboratories (Paris) for financial support.

REFERENCES AND NOTES

1. F. Arcamone, *Doxorubicin Anticancer Antibiotics*, Academic Press, New York, 1981 ; F. Arcamone, *Med. Res. Rev.*, 1984, 4, 153.
2. H. Tanaka, Y. Koyama, J. Awaya, H. Marumo, R. Oiwa, M. Katagiri, T. Nagai and S. Omura, *J. Antibiot.*, 1975, 28, 860.
3. H.W. Moore, *Science*, 1977, 197, 527.
4. N. Tanaka, T. Okabe, F. Isono, M. Kashiwagi, K. Nomoto, M. Takahashi, A. Shimazu and T. Nishimura, *J. Antibiot.*, 1985, 38, 1327 ; T. Okabe, K. Nomoto, H. Funabashi, S. Okuda, H. Suzuki and N. Tanaka, *J. Antibiot.*, 1985, 38, 1333.
5. W.J. Pigram, W. Fuller and L.D. Hamilton, *Nature New Biology*, 1972, 235, 17. G.J. Quigley, A.H.-J. Wang, G. Ughetto, G. Van Der Marel, J.H. Van Boom and A. Rich, *Proc. Natl. Acad. Sci. USA*, 1980, 77, 7204.
6. F. Bennani, J.C. Florent, M. Koch and C. Monneret, *Tetrahedron*, 1984, 40, 4669.
7. For use of (R)- and (S)-2,3-O-isopropylidene-glyceraldehyde in organic synthesis, see : J. Jurczak, S. Píkyl and T. Bauer, *Tetrahedron*, 1986, 42, 447.
8. C. Marschalk, F. Koenig and N. Ouroussoff, *Bull. Soc. Chim. Fr.*, 1936, 1545.
9. All new compounds gave i.r., n.m.r., m.s. and h.r.m.s. or combustion analysis consistent with their assigned structures.
10. Since the 7-OH (anthracycline numbering) as present in 9 was not required for

the present synthesis, the stereochemical course of the reaction was not determined.

11. The formation of 10 can be explained by the following mechanism :



12. D. Dominguez, R.J. Ardecky and M.P. Cava, *J. Am. Chem. Soc.*, 1983, 105, 1608.
13. 5,12-dihydroxy-3-hydroxymethyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11-dione (23) : $\text{C}_{18}\text{H}_{14}\text{O}_6$; ^1H n.m.r. (CDCl_3 , TMS) δ ppm : 13.67 and 13.62 (2 x 1H, 2s, D_2O exch., OH-5, OH-12), 8.37 (2H, m, H-7, H-10), 7.84 (2H, m, H-8, H-9), 4.93 (1H, d, $J = 10\text{Hz}$, H-1a), 4.87 (1H, d, $J = 10\text{Hz}$, H-1b), 4.13 (1H, m, H-3), 3.78 (1H, dd, $J = 11\text{Hz}$, $J' = 4\text{Hz}$) and 3.60 (1H, dd, $J = 11\text{Hz}$, $J' = 6\text{Hz}$) (CH_2OH), 3.18 (1H, dd, $J = 14\text{Hz}$, $J' = 5\text{Hz}$, H-4a), 2.89 (1H, dd, $J = 14\text{Hz}$, $J' = 8\text{Hz}$, H-4b), 2.53 (1H, br s, D_2O exch., CH_2OH).
14. (1S,3S)-5,12-dihydroxy-3-hydroxymethyl-1-methyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11-dione (24) : $\text{C}_{19}\text{H}_{16}\text{O}_6$; ^1H n.m.r. (CDCl_3 , TMS) δ ppm : 16.42 and 15.98 (2 x 1H, 2s, D_2O exch., OH-5, OH-12), 8.35 (2H, m, H-7, H-10), 7.82 (2H, m, H-8, H-9), 5.13 (q, $J = 6\text{Hz}$, H-1), 3.87 (1H, m, H-3), 3.73 (2H, m, CH_2OH), 2.91 (1H, dd, $J = 17\text{Hz}$, $J' = 2\text{Hz}$, H-4a), 2.60 (1H, dd, $J = 17\text{Hz}$, $J' = 10\text{Hz}$, H-4b), 2.15 (1H, br s, D_2O exch., CH_2OH), 1.58 (3H, d, $J = 6\text{Hz}$, CH_3).
15. (1R,3S)-5,12-dihydroxy-3-hydroxymethyl-1-methyl-3,4-dihydro-1H-anthra[2,3-c]pyran-6,11-dione (25) : $\text{C}_{19}\text{H}_{16}\text{O}_6$; ^1H n.m.r. (CDCl_3 , TMS) δ ppm : 16.20 and 16.07 (2 x 1H, 2s, D_2O exch., OH-5, OH-12), 8.35 (2H, m, H-7, H-10), 7.82 (2H, m, H-8, H-9), 5.27 (q, $J = 7\text{Hz}$, H-1), 4.11 (1H, m, H-3), 3.87 (1H, dd, $J = 11\text{Hz}$, $J' = 2\text{Hz}$) and 3.71 (1H, dd, $J = 11\text{Hz}$, $J' = 7\text{Hz}$) (CH_2OH), 2.87 (1H, dd, $J = 18\text{Hz}$, $J' = 4\text{Hz}$, H-4a), 2.60 (1H, dd, $J = 18\text{Hz}$, $J' = 11\text{Hz}$, H-4b), 2.11 (1H, br s, D_2O exch., CH_2OH), 1.64 (3H, d, $J = 7\text{Hz}$, CH_3).
16. H. Tanaka, Y. Koyama, T. Nagai, H. Marumo and S. Omura, *J. Antibiot.*, 1975, 28, 868.

Received, 24th September, 1986